Novo Nordisk aims to be ahead of the pharma pack with Iran investment
Add BT as a preferred source
Davos
DANISH drugmaker Novo Nordisk, the world's top insulin supplier, expects to be ahead of the pack now nuclear sanctions are lifted in Iran, thanks to a continuous presence and a pre-emptive investment plan.
The country is an attractive target for Big Pharma seeking to sell new medicines to its large and growing population, but going in at ground level and securing good relations with the authorities will be key, industry executives say.
